Table 2.

Treatment and Dose Modifications

	MTC (n = 8)	ATC (n = 10)	Total (N = 18)
Mean dose ± SD, mg	456 ± 191	590 ± 124	530 ± 167
Treatment duration, including time interrupted, weeks, median (range)	24.0 (12.3–40.0)	10.5 (2.9–32.1)	15.5 (2.9–40.0)
Dose reduction, n (%)	7 (88)	7 (70)	14 (78)
Reason for dose reduction, n (%)
Palmar-plantar erythrodysesthesia	5 (63)	3 (30)	8 (44)
Hypophosphatemia	1 (13)	1 (10)	2 (11)
Proteinuria	1 (13)	1 (10)	2 (11)
Rash maculopapular	2 (25)	0	2 (11)
Alopecia	1 (13)	0	1 (6)
Diarrhea	1 (13)	0	1 (6)
Decreased appetite	0	1 (10)	1 (6)
Dysphagia	0	1 (10)	1 (6)
Fatigue	0	1 (10)	1 (6)
Hypertension	0	1 (10)	1 (6)
Nausea	0	1 (10)	1 (6)
Vomiting	0	1 (10)	1 (6)
Drug interruption, n (%)	6 (75)	6 (60)	12 (67)
Reason for drug interruption
Palmar-plantar erythrodysesthesia syndrome	5 (63)	2 (20)	7 (39)
ALT increased	2 (25)	0	2 (11)
AST increased	1 (13)	1 (10)	2 (11)
Hypertension	0	2 (20)	2 (11)
Rash maculopapular	2 (25)	0	2 (11)
Arthritis	0	1 (10)	1 (6)
Decreased appetite	0	1 (10)	1 (6)
Dysphagia	0	1 (10)	1 (6)
Hypophosphatemia	0	1 (10)	1 (6)
Esophageal stenosis	0	1 (10)	1 (6)
Tumor hemorrhage	0	1 (10)	1 (6)
Permanent discontinuation, n (%)	2 (25)	1 (10)	3 (17)
Reason for permanent discontinuation, n (%)
ALT increased	2 (25)	1 (10)	3 (17)
AST increased	1 (13)	0	1 (6)

ALT, alanine aminotransferase; AST, aspartate aminotransferase.